Preoperative subconjunctival combined injection of bevacizumab and mitomycin C before the surgical excision of primary pterygium: clinical and histological results

• DOI: 10.2147/opth.s127700
• Publication Date: 2017-03-12T22:41:14Z
• Authors: Alahmady Hamad Al...; Gamal Abd Ellatei...; Mortada Ahmed Abo...; Usama Ali Mohammed; Nesreen Gamal Eld...
• Keywords: Pterygium; Sclera; Mitomycin C; CD31

Purpose: The aim of this study was to detect the clinical and histological effects preoperative subconjunctival injection both bevacizumab mitomycin C (MMC) 1 month before surgical excision primary pterygium using a bare sclera technique. Patients methods: A total 20 patients with underwent combined 0.1 mL MMC (0.1 mg/mL) (1.25 mg/0.1 mL) pterygium. excised tissues were examined histologically immunohistologically by CD31 staining, followed up clinically for at least 2 years. pterygia two without used comparison. Results: Clinically, there no intraoperative or postoperative complications. No recurrence noted during follow-up period. Histologically, previously injected showed decreased number epithelial cells stromal fibroblasts. latter rounded oval swollen rather than spindle shaped, some degenerating apoptotic. Collagen elastic fibers degenerated, distorted, in density, while blood capillaries obliterated. There significant decrease CD31-positive pterygia. Conclusion: Preoperative subpterygium is safe effective reducing Histological immunohistological changes form fibrovascular activity degeneration extracellular matrix nerve axons noted. Keywords: bevacizumab, C, changes, pterygium,